Supplier Advisory Panel

Dr Lindsay Ancelet
Market Access and Government Affairs Manager, GSK New Zealand

Lindsay’s role reflects a career that has been dedicated to advancing healthcare through the intersection of science, business, and policy.

She previously held senior roles at Pharmac, leading strategic and commercial decision-making for high-value medicine portfolios. Earlier in her career, she was a Maurice Wilkins Centre Research Fellow at the Malaghan Institute of Medical Research, specialising in immunology and cancer research.

Lindsay holds a PhD in Immunology from the University of Otago and studied at the Harvard Medical School Boston Children’s Hospital, the University of Toronto, the University of Saskatchewan, and Victoria University of Wellington. She contributes to shaping policy thinking on medicines access, vaccination, and health policy in New Zealand.

Kylie Earle
Market Access Lead, Sanofi, Australia & New Zealand

Kylie has almost 20 years’ experience developing and implementing successful reimbursement strategies, which have helped to support affordable access for patients to a broad range of treatments.

She holds a Bachelor of Medical Science (Honours) and a PhD in Neuroscience from the University of Sydney, and commenced her career in regulatory affairs in Australia, before moving to London into a global regulatory role.

On her return to Australia, she completed a Master’s in Public Health at the University of Sydney, transitioning into the market access space. As Sanofi’s Market Access Lead, Kylie is committed to working collaboratively with government, academia, healthcare professionals and patients to support timely and affordable access to innovative medicines and vaccines for consumers. 

Kate King
Director of Government Affairs (Australia/New Zealand), Medtronic

Kate leads Medtronic’s engagement on health policy and access to medical technologies. Her role is focused on shaping policies that support innovation, sustainable procurement, and timely patient access to medical devices. This involves working closely with governments, health agencies, and sector stakeholders across the Australia and New Zealand.

Kate is a prominent industry representative and currently serves as a Board Member of the Medical Technology Association of New Zealand (MTANZ), contributing to sector-wide advocacy and strategic engagement with the New Zealand health system. She regularly engages with the Ministry of Health, Health New Zealand, and Ministers on medical device management, procurement reform and innovation policy, and is a passionate advocate for the medical technology sector in New Zealand.

Francis Lawes
Access and Value Senior Manager (NZ), Pfizer

Francis is responsible for leading reimbursement strategy and engagement with Pharmac and broader health system stakeholders for Pfizer in New Zealand.

Originally trained as a pharmacist, he graduated from the University of Otago and brings 15 years’ pharmaceutical experience across Australia and New Zealand in a range of commercial and market access roles. He also holds a degree in business administration and is passionate about improving access to medicines for New Zealanders. 

Michaela Lion
Head of Value & Access and Government Affairs (NZ), AbbVie

Michaela leads AbbVie’s strategy work across reimbursement, health economics, and external policy engagement. She has extensive experience navigating the New Zealand medicines funding environment, including Pharmac processes, health technology assessment and stakeholder engagement across government and the health sector. 

Her experience spans work in New Zealand, Australia and the UK, including senior market access and health economics roles at AbbVie, and previous positions at Gilead, MSD/Merck, and consulting roles focused on HTA and outcomes research. 

She holds postgraduate qualifications in economics and from the University of Otago. and has undertaken health economics training through the University of York.

Liz Naylor
Market Access Lead (NZ), AstraZeneca

Liz has more than 25 years’ experience in pharmaceutical reimbursement, pricing, and government engagement. She is recognised for her expertise in Pharmac submissions, access strategy, and stakeholder advocacy across the New Zealand health system.

Prior to her role at AstraZeneca, Liz held senior leadership roles in market access and government affairs at Johnson & Johnson Innovative Medicine, where she led reimbursement and pricing strategies for multiple innovative therapies. Her career spans strategy development, policy engagement, and social investment initiatives, with a strong focus on improving patient access to innovative medicines.

Matt Needham
Director, Healthcare Ecosystem Partnering, Roche New Zealand

Matt specialises in reimbursement strategy, health technology assessment, and policy-related access challenges at Roche New Zealand. His work spans multiple therapeutic areas, including oncology, rare diseases, respiratory, cardiovascular, and ophthalmology.

Prior to joining Roche, he held senior market access roles at Takeda, Shire, and THEMA Consulting, where he supported PBAC/MSAC and international reimbursement submissions.

He holds academic qualifications in neuroscience and biotechnology commercialisation from the University of Otago and the University of Auckland, and regularly contributes to public discussions on medicines access and health policy in New Zealand. 

Angela Pantano
Chapter Lead, Access and Innovation, Roche Diagnostics NZ

Angela brings more than two decades of combined clinical, commercial, and health system experience across pharmaceuticals, medical devices, and diagnostics.

She began her career as a neonatal nurse and Nurse Practitioner before transitioning into industry roles spanning market access, public policy, sales, business development, and health system strategy.

Previously, Angela served as Roche Products NZ Director of Access and Public Policy, and has held leadership roles at Pacific Edge, the Medical Technology Association of New Zealand, Orion Health, and BrainZ Instruments.

She is recognised for her commitment to improving healthcare sustainability, advancing equitable access to innovation, and shaping system level change, drawing on experience that spans New Zealand and international markets. She holds a postgraduate degree in Health Sciences from Auckland University of Technology.